BACKGROUND: Induction chemotherapy with carboplatin followed by radiotherapy has been used for many years for treating intracranial germ-cell tumors (IC-GCTs) in Thailand. The objective of this study was to assess treatment outcomes, focusing on survival and ototoxicity. METHODS: The outcomes of all patients with IC-GCT treated at Ramathibodi Hospital and the Prasat Neurological Institute between 2000 and 2017 were reviewed and analyzed, including all patient characteristics and treatment modalities. Five-year overall survival (OS) and event-free survival (EFS) were analyzed using the Kaplan-Meier method, and factors affecting survival were compared using the log-rank test. RESULTS: Fifty-three patients age 1-14 years (median, 11 years) were included in this study. The median follow-up time was 63 months. The 5-year EFS and OS rates were 94.3% and 96.2% for all patients, respectively. No statistical difference in OS or EFS was observed between the data of recipients in the carboplatin-based and historical cisplatin-based therapies in our institutes. Concerning radiotherapy, omission of radiotherapy or focal irradiation results in worse long-term survival outcomes, but reduction in dose of radiotherapy to less than 40 Gy did not cause any negative impact on survival rates. Furthermore, carboplatin was associated with lower rates of hearing loss than cisplatin (5.7% vs 87.5%). CONCLUSIONS: Induction chemotherapy with carboplatin-based regimens was associated with excellent survival rates and low ototoxicity in patients with IC-GCT. Radiotherapy should be given to all patients with a minimal volume equivalent to whole-ventricular radiotherapy, during which doses of lower than 40 Gy can be effectively used.
BACKGROUND: Induction chemotherapy with carboplatin followed by radiotherapy has been used for many years for treating intracranial germ-cell tumors (IC-GCTs) in Thailand. The objective of this study was to assess treatment outcomes, focusing on survival and ototoxicity. METHODS: The outcomes of all patients with IC-GCT treated at Ramathibodi Hospital and the Prasat Neurological Institute between 2000 and 2017 were reviewed and analyzed, including all patient characteristics and treatment modalities. Five-year overall survival (OS) and event-free survival (EFS) were analyzed using the Kaplan-Meier method, and factors affecting survival were compared using the log-rank test. RESULTS: Fifty-three patients age 1-14 years (median, 11 years) were included in this study. The median follow-up time was 63 months. The 5-year EFS and OS rates were 94.3% and 96.2% for all patients, respectively. No statistical difference in OS or EFS was observed between the data of recipients in the carboplatin-based and historical cisplatin-based therapies in our institutes. Concerning radiotherapy, omission of radiotherapy or focal irradiation results in worse long-term survival outcomes, but reduction in dose of radiotherapy to less than 40 Gy did not cause any negative impact on survival rates. Furthermore, carboplatin was associated with lower rates of hearing loss than cisplatin (5.7% vs 87.5%). CONCLUSIONS: Induction chemotherapy with carboplatin-based regimens was associated with excellent survival rates and low ototoxicity in patients with IC-GCT. Radiotherapy should be given to all patients with a minimal volume equivalent to whole-ventricular radiotherapy, during which doses of lower than 40 Gy can be effectively used.
Authors: Claire Alapetite; Herve Brisse; Catherine Patte; Marie Anne Raquin; Genevieve Gaboriaud; Christian Carrie; Jean Louis Habrand; Philippe Thiesse; Jean Claude Cuilliere; Valerie Bernier; M Ben-Hassel; Didier Frappaz; Marie Christine Baranzelli; Eric Bouffet Journal: Neuro Oncol Date: 2010-08-17 Impact factor: 12.300
Authors: Nasjla Saba da Silva; Andrea M Cappellano; Blanca Diez; Sergio Cavalheiro; Sharon Gardner; Jeffrey Wisoff; Stewart Kellie; Robert Parker; James Garvin; Jonathan Finlay Journal: Pediatr Blood Cancer Date: 2010-03 Impact factor: 3.167
Authors: Y Shibamoto; M Abe; J Yamashita; M Takahashi; M Hiraoka; K Ono; K Tsutsui Journal: Int J Radiat Oncol Biol Phys Date: 1988-08 Impact factor: 7.038
Authors: Suntae Ji; Hee Won Chueh; Ju Youn Kim; Su Jin Lim; Eun Joo Cho; Soo Hyun Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo Journal: Korean J Pediatr Date: 2011-03-31
Authors: E Bouffet; M C Baranzelli; C Patte; M Portas; C Edan; P Chastagner; F Mechinaud-Lacroix; C Kalifa Journal: Br J Cancer Date: 1999-03 Impact factor: 7.640
Authors: Lorena V Baroni; Agustina Oller; Candela S Freytes; Claudia V Sampor; Natalia Pinto; Nicolas Ponce Fernandez; Carlos Rugilo; Fabiana Lubieniecki; Pedro Zubizarreta; Daniel Alderete Journal: J Neurooncol Date: 2021-03-03 Impact factor: 4.130